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Background: Low-dose spiral computed tomography (LDSCT) in comparison to conventional chest X-ray proved to
be a highly sensitive method of diagnosing early stage lung cancer. However, centrally located early stage lung
tumours remain a diagnostic challenge. We determined the practicability and efficacy of early detection of lung
cancer when combining LDSCT and sputum cytology.
Methods: Of a cohort of 4446 formerly asbestos exposed power industry workers, we examined a subgroup of
187 (4.2%) high risk participants for lung cancer at least once with both LDSCT and sputum cytology. After the
examination period the participants were followed-up for more than three years.
Results: The examinations resulted in the diagnosis of lung cancer in 12 participants (6.4%). Six were in clinical
stage I. We found 10 non-small cell lung carcinomas and one small cell lung carcinoma. Sputum specimens showed
suspicious pathological findings in seven cases and in 11 cases the results of LDSCT indicated malignancies. The
overall sensitivity and specificity of sputum cytology was 58.0% and 98% with positive (PPV) and negative (NPV)
predictive values of 70% and 97%. For LDSCT we calculated the sensitivity and specificity of 92% and 97%. The PPV
and NPV were 65% and 99% respectively.
Conclusions: Our results confirmed that in surveillance programmes a combination of sputum cytology and LDSCT
is well feasible and accepted by the participants. Sputum examination alone is not effective enough for the
detection of lung cancer, especially at early stage. Even in well- defined risk groups highly exposed to asbestos, we
cannot recommend the use of combined LDSCT and sputum cytology examinations as long as no survival benefit
has been proved for the combination of both methods. For ensuring low rates of false-positive and false-negative
results, programme planners must closely cooperate with experienced medical practitioners and pathologists in a
well-functioning interdisciplinary network.
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Lung cancer remains one of the leading types of cancer
in the world. In 2008 1.61 million new cases of lung
cancer occurred and 1.38 million people died [1]. Ac-
cording to the American Cancer Society, the total num-
ber of deaths from all types of lung cancer in the United
States for the year 2010 still exceeded that from colon-,
breast- and prostate cancers combined [2]. The huge
and worldwide public health importance of lung cancer
urgently calls for effective and affordable health inter-
ventions. The primary objectives should be early detec-
tion and treatment in addition to smoking cessation
programmes. In the 1970s, the National Cancer Insti-
tute of America sponsored three mass-screening pro-
grammes using chest X-rays and sputum cytology [3-5].
No differences in mortality were observed between the
intervention and control groups [6]. As a result of these
and other studies, mass screening for lung cancer was
not recommended [7]. In recent studies, where the
highly sensitive method of low-dose spiral computed
tomography (LDSCT) was used instead of conventional
chest X-rays, a higher detection rate of early-stage lung
cancers could be demonstrated. But the design of these
uncontrolled and non-randomised studies was un-
suitable to demonstrate that screening with LDSCT de-
creases mortality [8]. Consequently, medical guidelines
did not recommend lung cancer screening in indivi-
duals, when they do not have specific symptoms or an
increased disease risk [9,10]. Recent results from the
National Lung Screening Trial confirmed a decreasing
effect of LDSCT screening on mortality, particularly in
those with a high risk of lung cancer [11].
Smoking is the predominant risk factor for lung can-
cer with a 23 times higher risk in male smokers com-
pared to non-smokers [2,12]. Additional environmental
and occupational risk factors are also relevant for the
development of lung cancer. Exposure to asbestos dust,
especially in combination with cigarette smoke, is a
main occupational cause of lung malignancies [13-16].
The health effects of asbestos dust are difficult to mea-
sure and control. Some reasons for that are the long
latency periods (12–37 years) between exposure and the
occurrence of lung cancer and the widespread, unpro-
tected use in the past [17].
In this study, we tested the hypothesis that non-
automated sputum cytology may be particularly useful
for the diagnosis of centrally located tumours [18,19],
whereas LDSCT is more capable of detecting tumours
in the peripheral parts of the lung. Following that no-
tion, the best detection rates of early stage lung cancer
would be in theory expected by applying both methods.
We examined the practicability and efficacy of lung can-
cer screening in a group of power industry workers,
who were heavily exposed to asbestos dust in the past.Methods
Our study cohort included 5632 formerly asbestos ex-
posed employees of a major provider of electrical power
in Germany. They had been enrolled after confirming by
signature some contact with asbestos fibres in the past
and giving written consent to participate. Most partici-
pants had been involved in general maintenance and re-
pair work in various installations of power generation,
including lignite fuelled power plants. Routine occupa-
tional tasks involved the handling of asbestos and asbes-
tos containing materials such as the removal of asbestos
lagging around the turbines and the spraying of asbestos
pulp. The work was carried out without effective per-
sonal protective measures or technical ventilation [20].
All medical examinations were done in the framework
of a health surveillance programme, which had been set
up for the formerly exposed employees with the primary
objective to detect newly developing lung cancers in an
early stage. Before starting the examinations, we recorded
age, tobacco consumption and duration of asbestos expo-
sure for all 5632 participants, assuming that these were
the major risk factors for lung cancer development. The
required data were collected via self-administered ques-
tionnaires. Based on this information, all study partici-
pants were allocated to one of three risk groups with an
assumed low, medium and high risk of developing lung
cancer. For risk stratification, we combined the factors
duration of asbestos exposure in years, age and smoking
status as follows: duration × [age/50]3 × smoking (0.1 =
non-smoker, 0.3 = ex-smoker, 1.0 = smoker) [21]. Between
March 2002 and December 2006 a total of 4446 (78.9%)
participants were examined at least once for asbestos
related diseases. Routine examinations included occupa-
tional history, medical history, standard interview on
current respiratory symptoms, physical examination of the
thorax and lung function testing. In contrast to the stan-
dard chest X-ray in the other participants, the high risk
group was examined annually with LDSCT of the thorax
and sputum cytology. Automated sputum-cytometry with
certified instruments was not available in Germany at the
time sputum samples were obtained for this study. Out of
those examined, 3182 participants belonged to the low,
1001 to the medium and 263 to the high risk group. For
the analysis presented here, we focused on high risk par-
ticipants who were not older than 75 years on the refe-
rence date of 1 September 2002. This was based on the
assumption that all other participants, particularly those
in the low risk group and those older than 75 years, would
have benefitted significantly less from a combined examin-
ation with sputum cytology and LDSCT. That way we en-
sured for most of our study group an acceptable balance
between the likelihood of lung cancer and the possible
harms from false-positive sputum findings. Participants,











Figure 1 Flow chart for processing the findings of the low-dose
spiral computed tomography of the thorax. aLDSCT = low-dose
spiral computed tomography, bNon calcified nodules 6 - ≤10 mm,
c3, 6 or 12 month follow-up with LDSCT, depending on size
of nodule.
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ing methods or had no usable results because of other rea-
sons, were excluded from the analysis (n = 76). Our
evaluation included 187 high risk participants who fulfilled
all admission criteria [21]. They represented 4.2% of those
examined (n = 4446) and 3.3% of the total cohort (n =
5632). The research was performed according to the prin-
ciples of the World Medical Association’s Declaration of
Helsinki and obtained approval by the Institutional Review
Board of the Medical Faculty of RWTH Aachen University
(registration number EK2205).
Computed tomography scans
Computed tomography examinations were carried out in
a low-dose spiral technique applying 10 mAseff. for per-
sons weighing less than 80 kg, and 20 mAseff. for persons
weighing more than 80 kg. No contrast material was
administered. All CT-scans were performed with a
16-slice MDCT scanner (SOMATOM Sensation 16,
Siemens Medical Solutions, Forchheim, Germany) using
the following parameters: 16 × 0.75 mm collimation, ro-
tation time 0.5 sec, table feed/rotation 18 mm. For lung
nodule detection a stack of images was reconstructed
with 1 mm slice thickness and 0.5 mm increment using
a sharp reconstruction kernel (Siemens B50 kernel) and
a window centre of −400 HU and a width of 2000 HU.
The initial reading was done by an experienced clinical
radiologist (MD) at a standard PACS reading worksta-
tion (Barco, Philips/Sectra, Stockholm, Sweden). Data
were then transferred to a workstation for further evalu-
ation using dedicated lung analysis software (LungCare™,
Siemens Medical Solutions, Forchheim, Germany). All
CT-scans were routinely re-read by an occupational
physician with special experience in the diagnosis of as-
bestos related diseases (TK). The follow-up algorithm
applied for lung nodules has been described elsewhere
[21]. In cases with suspicious lung nodules and other
pathological findings we recommended a clinical work-
up in cooperation with the clinical departments of
Internal Medicine, Diagnostic Radiology, Heart and
Thorax Surgery, and Radiotherapy (Figure 1).
Sputum cytology
During medical examination, all participants were
instructed in detail on how to generate good sputum
samples, how to deposit them in the prepared containers
and how to send them to the study laboratory in prepaid
envelopes. For sputum collection we used plastic tubes
with a screw cap, one for each specimen, containing ca.
50 ml of a fixing solution with 50% ethanol, 2% car-
bowax 1540 and 0.006% rifampicin [22].
The cytological results were categorized in “regular”
for normal or inflammatory sputa and “irregular” or
“equivocal” for sputa with squamous cell metaplasia incombination with mild or moderate dysplasia (Figure 2).
Further categories were “suspicious” for sputa with squa-
mous cell metaplasia and severe dysplasia or very few
abnormal cells, and “pathological” for sputa containing
malignant cells. In cases of “insufficient” sputum speci-
mens, we requested the participants to send in a new
sputum sample as soon as possible. If the assessment
was “equivocal” we asked the participants to collect a
second set of samples after about three months. In cases
of “suspicious” or “pathological” results, we recom-
mended immediate clinical work-up. Appointments with
clinicians could be arranged at any time in the frame-
work of the surveillance programme.
A pathological sputum result was considered truly
positive if it was confirmed by tissue biopsy or the
LDSCT finding clearly indicated lung cancer. Diagnosed
lung tumours were classified according to the TNM
staging system and their radiological localisation [23].
Tumours located distal to the segmental bronchus were
classified as peripheral, all others were considered as
centrally located.
Re-examination
In July 2006 when this study was terminated, 187 parti-
cipants had been examined at least once with a combi-
nation of LDSCT and sputum cytology. Re-examinations
after one year and later were possible only in those par-
ticipants who had their initial examination in or before
July 2005. Other reasons for missing re-examination data
were refusal to participate again, lack of consent to one
of the two investigations and inability to attend because


















Figure 2 Flow chart for processing the sputum findings. aParticipants were requested to send in a new sputum sample as soon as possible.
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re-examined with both methods one year, 66 (35%) two
years and 12 (6%) three years after the initial contact.
Thus our data pool included the results of 382 parallel
examinations with sputum cytology and CT-scan of the
thorax.Follow-up period
Between August 2006 and the end of 2009 we recorded all
new cases of lung cancer in the cohort and analysed their
pre diagnosis results during the active study period. That
provided us with some indication on the predictive value
of LDSCT and sputum cytology. As the study design pre-
cluded retrospective analysis of the clinical records back-
wards from 2009, we evaluated the occupational disease
register of the BGETEM as the main secondary source. As
an additional source of information, we used death certifi-
cates filed before the end of 2009 and indicating the diag-
nosis of lung cancer.Table 1 Asbestos exposure and other risk factors in the
study group (n =187)
Mean SD Range
Age (years) 65.8 5.8 46 – 78
Time since first exposure (years) 40.4 7.8 26 – 60
Duration of asbestos exposure (years) 29.5 7.7 15 – 49
Pack years 44.7 47.9 0 – 118Statistical analysis
The sensitivity and specificity of the cytological and radio-
logical investigations was tested against the final diagnosis
of lung cancer after three years of follow-up. Furthermore,
we calculated the positive (PPV) and negative predictive
values (NPV) of sputum cytology and computed tomo-
graphy. As gold standard for diagnosis, we used the biopsy
results obtained in the process of clinical work-up. Calcu-
lations of statistical parameters such as sensitivity and spe-
cificity were based on the combined results of LDSCT and
cytology obtained in the active study period (baseline and
re-examination).Results
The burden of asbestos exposure and the results for the
risk factors age, latency period and cigarette smoke are
shown in Table 1. Latency is defined here as the time
period between first exposure to asbestos and the date
of the initial examination, covering periods of up to
60 years. As some participants were exposed from the
beginning of their apprenticeship until retirement age
there was a wide range of exposure duration of approxi-
mately 35 years. When comparing mean age and latency
period, it seems that asbestos exposure started for many
participants in their mid-twenties. The mean pack year
value was calculated including the results of the active
smokers and participants with smoking periods of less
than one year.
New cases of lung cancer during the examination period
In the active study period 12 participants were newly di-
agnosed with lung cancer (6.4%), 11 of them confirmed
with lung tissue biopsy (Table 2). One of the 12 patients
(case number four) died suddenly before the diagnosis
could be confirmed with lung biopsy. As the patient had
clear clinical signs with weight loss of 28 kg within
six months together with a fast growing lung nodule
Table 2 Cases of lung cancer among 187 high risk participants with CT scan and sputum examination
No. Examinationa Locationb Diagnosisc Histologyd Stage Survivale
1 b per CT + spu SQC IIIa
2 r per CT + spu SQC Ia 29
3 b per CT ADO Ia
4g b per CT 7
5 r per CT LAC IIIb 23
6 b per CT ADO Ia 64
7 b cen CT + spu SQC IV 21
8 b cen CT + spu SQC Ia
9 r cen CT + spu SQC IIb 33
10 b cen CT + spu SQC Ib 18
11 b cen CT SMC Ia 28
12 r cen spu SQC IIIb 72
13 i cen SMC IIb 14
14 i 35
15h f
16 f SMC IIIb k
17 f SMC IIb k
18 f IIIb k
aExamination with significant result: b = baseline, r = re-examination, i = interval, f = follow-up.
bLocation of tumour: per = peripheral, cen = central.
cResult indicating diagnosis: CT = low-dose spiral computed tomography, spu = sputum cytology.
dHistology of lung carcinoma: SQC = squamous cell, ADO = adeno, LAC = large cell, SMC = small cell.
eSurvival time after beginning of initial clinical symptoms indicating the disease (months).
gDied suddenly 2004 before biopsy could be taken, diagnosis unequivocal clinically and on CT.
hDied 2008 with lung cancer after refusing further examinations.
kAlive by the end of follow-up.
In patients with missing data the documented histories were incomplete or could not be retrieved in time.
Table 3 Participants with newly diagnosed lung cancer
during the examination period: comparison of sputum
cytology with the results of low-dose spiral computed
tomography (LDSCT) of the thorax for the whole cohort
(n = 187)
Lung cancer No lung cancera Totalb
Sputum cytology
Suspicious or pathologicalc 7 3 10
Regular or equivocald 5 172 177
LDSCT
Suspicious 11 6 17
Regular 1 169 170
Cytology and LDSCT
At least one positive 12 8e 20
Both negative 0 167 167
aIncluding six lung cancer patients falling ill outside the examination period.
bThe totals of test results in each group add up to n = 187.
cIn at least one sputum sample.
dIn all samples tested.
eIn one participant, both results were positive.
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him also as a confirmed case of progressive lung cancer.
Eight lung cancers were diagnosed at the first combined
examination (baseline), four at the first re-examination
and two in the interval between the baseline examin-
ation and the first re-examination. One of the two (case
number 13) was diagnosed in an external hospital after
symptoms developed. We found ten cases of non-small
cell lung carcinoma (NSCLC) and one small cell lung
carcinoma (SCLC). Of the 11 participants with biopsy
confirmation, six were in clinical stage I, one in stage II,
three in stage III and one in stage IV. In half of the 12
confirmed cases the tumours were located in the peri-
phery of the lung.
Sputum cytology
In seven cases with newly diagnosed primary lung cancer,
sputum specimens showed suspicious or pathological
findings (Table 3). In three other cases with suspicious or
pathological sputum specimens, no malignant lung tu-
mours were detected and therefore considered as false
positive (false positive rate 1.7%). In the remaining five
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showed no signs of malignancy and were considered as
false negative (false-negative rate 42%). Four of these were
peripheral tumours. When comparing the results of spu-
tum cytology with the total number of confirmed lung
cancer cases mostly diagnosed with biopsy, we calculated
the sensitivity and specificity of cytology with 58% and
98%. The positive (PPV) and negative (NPV) predictive
values were 70% and 97%.Computed tomography
In 11 cases the results of computed tomography indi-
cated malignant lung disease (Table 3). One lung cancer
that could not be detected on LDSCT was a patient with
a central nodule later diagnosed as squamous cell car-
cinoma. As the simultaneously done sputum cytology
showed a pathological result, that case was counted as a
false negative CT result (false negative rate 8.3%). In
another six cases with radiological signs of pulmonary
or pleural malignant disease the results of clinical work-
up did not confirm the radiological diagnosis. Three
patients suffered from tuberculoma, an atypical pneu-
monia and one was diagnosed with dystelectasis of
unknown origin. Another two patients showed radio-
logical signs of progressive pleural thickening, con-
sistent with early stage malignant pleural mesothelioma.
After explorative surgery including pleural and pulmo-
nary biopsies the final diagnosis of chronic proliferative
pleurisy with signs of early lung fibrosis was made. The
remaining patient had a large pulmonary nodule, which
showed no signs of growth over a period of 46 months
and was therefore no longer seen as suspicious (false
positive rate 3.4%). For the CT results, we calculated a
sensitivity and specificity of 92% and 97%. The PPV and
NPV were 65% and 99% respectively. When combining
the results of both methods (Table 3), we obtained an
overall sensitivity and specificity of 100% and 95%, with
a PPV of 60% and a NPV of 100%.New cases during follow-up
Of the remaining six patients with lung cancer indicated
in Table 2 (cases 13 to 18), two developed their disease
in the period between routine examinations (interval)
and four after the examination period in August 2006
and the conclusion of follow-up by the end of 2009 (fol-
low-up). None of these patients had pathological or
equivocal findings on LDSCT or with sputum cytology
in the baseline or re-examinations. The time period bet-
ween last examination and recorded date of diagnosis
lay between 17 and 19 months. In three of the patients
we could secure a histological confirmation of the diag-
nosis lung cancer, one patient died in the year 2008 after
refusing further examinations.Discussion
The various forms of lung cancer are increasingly com-
mon and remain difficult to treat. As long as occupational
and environmental causes of lung cancer, such as expo-
sure to asbestos dust and tobacco smoking, cannot be
abolished and the chance of recovery mainly depends on
the stage of the disease, the early detection of lung cancer
is the primary objective of focused health interventions.
As the search for an effective biomarker indicating early
disease was not successful so far, a combination of sensi-
tive radiological imaging and a filter for detecting high risk
individuals seems the most promising approach at present.
Our study was based on the simultaneous use of sensitive,
state-of-the-art radiological imaging and elaborate sputum
cytology applied to a highly selected group of individuals.
In theory, the combined use of imaging and cytology
should help to further reduce the “blind spot” of radio-
logical imaging regarding the early detection of central
lung tumours. Other complementary screening strategies
for lung cancer are under investigation, but they are either
too invasive as a first-step screening method, such as
fluorescence bronchoscopy, or their practical value has
not been proven yet, such as exhaled breath analysis
[24,25]. Our hypothesis was that parallel cytology could
detect invisible, early stage central tumours or quickly
confirm the malignant nature of tumours with a difficult
location for taking biopsies. However, our highly selected
but small study group together with the limited follow-up
period were serious limitations for testing that hypothesis.
It was possible that we might have missed some patients
with newly diagnosed lung cancer, who were alive and
were not reported to the BGETEM as suspect cases of oc-
cupational lung cancer. We would also have missed de-
ceased lung cancer patients with a false or misleading
diagnosis on their death certificates. From a practical
point of view, the secondary objective of establishing a
novel approach under routine working conditions ap-
peared almost as important. While sputum cytology in
combination with other screening methods has been
tested before, there are no recent reports on larger scale
use together with LDSCT in asbestos exposed individuals
[25-27]. Our evaluation should therefore also be seen as
a contribution to the debate, whether or not a formerly
asbestos exposed participant of an early detection pro-
gramme for lung cancer is willing to undergo additional,
often inconvenient sputum testing. Large scale health pro-
grammes, even in individuals with an increased risk of dis-
ease, would be open for criticism when launched without
convincing evidence of both, increased survival and re-
duced all-cause mortality. Due to scope and design of the
study, we could not assess the overall effectiveness of lung
cancer screening in asbestos exposed individuals. How-
ever, our results provide good indication of the value of a
combined approach using CT-scans and sputum cytology.
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caused by the exposure to airborne asbestos, the iden-
tification of high-risk individuals is complicated by the
formerly widespread, unprotected use of asbestos and the
extremely long latency periods between exposure and dis-
ease. In our effort to form a high-risk group, who would
benefit most from lung cancer screening, we linked the
data on asbestos exposure with age and smoking habits,
which resulted in a highly selected group of 4.2% of the
total [21]. We could therefore assume with some certainty
that the participants most at risk of developing lung can-
cer were included in the study group. However, it was also
clear that the exposure data based on self-administered
questionnaires might have been affected by a potential
recall bias, especially in those who had started work
several decades before. The data on cumulative exposure
to asbestos and tobacco smoke (Table 1) should therefore
be seen in the light of the long time periods since first
exposure, stretching in some over an entire working life,
and interpreted with caution.
Examination methods
In large-scale surveillance programmes, examination
methods must be easy to handle and fit into tight wor-
king schedules. The methods should be standardized,
not invasive and easily tolerated by the participants. The
values for sensitivity and specificity should be well over
90%. In the light of these requirements, LDSCT seems
to be an examination method, which is well suited for
health surveillance. CT-scans can be performed within a
few seconds, not causing any physical inconvenience or
requiring a specific activity by the patient. The method
of sputum collection at home is not invasive and is also
a well-accepted procedure. Nevertheless, this technique
is little standardized and the collection of sputum sam-
ples at home precludes technical guidance by an ex-
perienced person. It was therefore impractical to use
induced sputum samples which would have required
some technical support for the saline aerosol inhalation
as usually only available at hospital. It was however clear
that sputum induction would have allowed better quality
samples and more valid results. In the context of our
study, the approach of routine sputum sampling still
proved to be a well feasible and acceptable surveillance
method.
False-positive results
For participants with false positive results, the exami-
nation with LDSCT or sputum cytology had significant
consequences. They usually underwent invasive and ac-
tually unnecessary examinations such as lung biopsy or
thoracotomy with the risk of adverse effects and poten-
tially even affecting the survival time of the individual.
Health surveillance programmes for the early detectionof lung cancer with high rates of false positive findings
would be ineffective and difficult to justify. Humphrey
et al. described recent LDSCT studies in which the false
positive rates ranged from 5% to 50% of prevalence and
3% to 12% of incidence [8]. While in our study the false
positive rates were minimal in comparison (1.7% with 3
of 175 sputum examinations and 3.4% with 6 of 175
LDSCT examinations), the positive predictive values of
70% and 65% respectively, and the resulting precision of
sputum cytology and LDSCT were unsatisfactory. When
combining the results of both methods, the resulting
PPV of 60% was still lower. This was accompanied by a
corresponding increase of sensitivity to 100%. Eight par-
ticipants had to undergo actually unnecessary further in-
vestigations, which were however limited to sputum and
CT controls after three months in the three participants
with irregular sputum results. When defining as “false-
positive” only those results leading to invasive clinical
work up with negative outcome, we had no false positive
sputum results.
Another important aspect when considering the con-
sequences of false positive screening results was the fact
that individuals informed on the results will usually ex-
perience an extended period of anxiety and concern be-
fore the results were confirmed false. That was also the
case with one of our participants, who was admitted to a
psychiatric institution for treatment of depression after
being informed that a lung nodule suspicious of lung
cancer had been found. It seems therefore essential that
large scale early detection programmes for life threaten-
ing diseases such as lung cancer are carried out with the
support of a network of specialists also including psy-
chologists and psychiatrists, who can attend to indi-
vidual patients.
Sputum findings
In a review of 16 representative studies to assess the sen-
sitivity of sputum cytology, values ranging from 42% to
97% were calculated, depending on the location of the
lesions [19]. However, the variety of methods made it
difficult to assess the validity of these data. In our study,
the calculated sensitivity of sputum cytology was with
58% low in comparison with the value for LDSCT
of 92%. We considered the finding that one centrally
located lung tumour invisible on LDSCT was detected
by sputum cytology (in stage IIIb) as at least demonstra-
ting the potential benefit of the method in a surveillance
effort.
One of the false negative cases was equivocal for sputa
with squamous cell metaplasia with moderate dysplasia
(grade II). For such cases, we recommended a control spu-
tum examination after three months (Figure 2). If imme-
diate clinical work-up (Figure 2, dotted line) would be
done, the rate of false-negative findings could be reduced
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value would also have decreased from 70% to 53.8%,
resulting in a reduced precision of sputum cytology and
more false-positive results. To identify malignant cells by
means of sputum cytology requires experienced personnel
with a high degree of expertise. Sputum analysis using
DNA image cytometry as an automated computer-assisted
method to detect malignant cells may be an alternative,
which is more suitable for widespread routine use.
Sputum cytometry alone or better in combination with
sputum cytology might increase the sensitivity of sputum
examinations by 70 to 90% [28-30].
Location of lung tumours
The importance of tumour location on the sensitivity of
sputum cytology has been described in previous studies
[19,31]. Most of them showed decreased sensitivity for
peripherally located masses, others could not find any
difference. Our results seemed to indicate that centrally
located tumours were diagnosed more often by sputum
cytology (83%) than peripheral tumours (33%). One
plausible explanation might be the closer contact of cen-
tral tumours to the bronchogenic system. It may well be
that in cases with a centrally located tumour the closer
contact to the bronchogenic system could compensate
for the higher risk of a false negative result of the CT
scan. That risk is further increased by the standard tech-
nique of CT without contrast material.
Follow-up
Participants with normal examination results, who were
diagnosed with lung cancer during follow-up, might be
seen as “false negative” cases. However, the delay between
examination and diagnosis let it appear unlikely that any
signs of a developing carcinoma could have been picked
up by CT scan or sputum cytology. The fact that four
cases among a group of about 200 over a period of more
than three years corresponded roughly with the expected
true incidence may also indicate that specific symptoms
and detectable signs of disease developed only after the
examinations. As none of the participants with false posi-
tive results developed disease during follow-up, we can
assume that they were truly false positive cases and the
applied algorithm was effective in ruling out early stage
lung disease.
Conclusions
Our results confirmed that (1) in surveillance programmes
a combination of sputum cytology and LDSCT is well
feasible and accepted by the participants. (2) Sputum
examination alone is not effective for the detection of
early stage lung cancer. (3) In high risk individuals, the
combination of LDSCT scans and sputum cytology is
probably more effective in detecting early lung cancerthan LDSCT alone. However, the combination of both
methods cannot be generally recommended as long as
there is no evidence of a significant reduction of mortality
and an improvement in overall survival. (4) For keeping
false-positive and false-negative findings low, it is essential
to ensure close cooperation with experienced clinicians
and pathologists in a well-established interdisciplinary
network.
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